• ATB-346 is a hydrogen sulfide-releasing derivative of naproxen
• H2s has been shown to play important role in the maintenance of gastric mucosal integrity.

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) announced on 8/29/18 that it has prepared a comprehensive report of the recently-completed Phase 2B study for its lead drug, ATB-346. The study was completed in March 2018 and demonstrated unequivocal superiority in gastrointestinal (“GI”) safety compared to naproxen, the most prescribed NSAID in the United States.

The report provides a discussion of the study objectives and design, an analysis of the primary and secondary outcomes and additional effectiveness and safety parameters, and a brief discussion of the possible mechanisms related to the metabolism of ATB-346 responsible for the favourable pharmacokinetics and enhanced cyclo-oxygenase (COX) inhibition. The review article is available for download on Antibe’s website at: http://www.antibethera.com/news-media/scientific-publications/.

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. Endogenous hydrogen sulfide (H2s) and H2s delivered via an H2s donor have been shown to play important role in the maintenance of gastric mucosal integrity. NSAIDs are the most commonly used therapy for osteoarthritis, yet their use is associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also widely used in conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, and general pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. It is well-accepted that patients with these conditions would benefit greatly from an effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent such as ATB-346.